Clinical trial report

TMC278 (Rilpivirine) versus efavirenz as initial therapy in treatment-Naïve, HIV-1-infected patients

Research output: Contribution to journalArticle

4 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)1-3
Number of pages3
JournalCurrent Infectious Disease Reports
Volume13
Issue number1
DOIs
StatePublished - Feb 1 2011
Externally publishedYes

Fingerprint

Rilpivirine
efavirenz
HIV-1
Clinical Trials
Therapeutics

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

@article{1fa57f940eea44b28bbafa32e9c9f4d1,
title = "Clinical trial report: TMC278 (Rilpivirine) versus efavirenz as initial therapy in treatment-Na{\"i}ve, HIV-1-infected patients",
author = "MacArthur, {Rodger David}",
year = "2011",
month = "2",
day = "1",
doi = "10.1007/s11908-010-0148-6",
language = "English (US)",
volume = "13",
pages = "1--3",
journal = "Current Infectious Disease Reports",
issn = "1523-3847",
publisher = "Current Science, Inc.",
number = "1",

}

TY - JOUR

T1 - Clinical trial report

T2 - TMC278 (Rilpivirine) versus efavirenz as initial therapy in treatment-Naïve, HIV-1-infected patients

AU - MacArthur, Rodger David

PY - 2011/2/1

Y1 - 2011/2/1

UR - http://www.scopus.com/inward/record.url?scp=79551550417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551550417&partnerID=8YFLogxK

U2 - 10.1007/s11908-010-0148-6

DO - 10.1007/s11908-010-0148-6

M3 - Article

VL - 13

SP - 1

EP - 3

JO - Current Infectious Disease Reports

JF - Current Infectious Disease Reports

SN - 1523-3847

IS - 1

ER -